These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 17434893)

  • 1. Targeted therapy in nuclear medicine--current status and future prospects.
    Oyen WJ; Bodei L; Giammarile F; Maecke HR; Tennvall J; Luster M; Brans B
    Ann Oncol; 2007 Nov; 18(11):1782-92. PubMed ID: 17434893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Therapeutic advances of nuclear medicine in oncology].
    Valdés Olmos RA; Hoefnagel CA; Bais E; Boot H; Taal B; de Kraker J; Vote PA
    Rev Esp Med Nucl; 2001 Dec; 20(7):547-57. PubMed ID: 11709141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Experience with indium-111 and yttrium-90-labeled somatostatin analogs.
    Virgolini I; Traub T; Novotny C; Leimer M; Füger B; Li SR; Patri P; Pangerl T; Angelberger P; Raderer M; Burggasser G; Andreae F; Kurtaran A; Dudczak R
    Curr Pharm Des; 2002; 8(20):1781-807. PubMed ID: 12171531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic nuclear medicine in pediatric malignancy.
    Schmidt M; Baum RP; Simon T; Howman-Giles R
    Q J Nucl Med Mol Imaging; 2010 Aug; 54(4):411-28. PubMed ID: 20823809
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What can be expected from nuclear medicine tomorrow?
    Barbet J; Kraeber-Bodéré F; Chatal JF
    Cancer Biother Radiopharm; 2008 Aug; 23(4):483-504. PubMed ID: 18771353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Present status and progress of endocrine nuclear medicine].
    Nakajo M
    Kaku Igaku; 1999 Jan; 36(1):1-5. PubMed ID: 10087759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dosimetry in nuclear medicine therapy: what are the specifics in image quantification for dosimetry?
    Bardiès M; Buvat I
    Q J Nucl Med Mol Imaging; 2011 Feb; 55(1):5-20. PubMed ID: 21386782
    [No Abstract]   [Full Text] [Related]  

  • 8. Staging and treatment of differentiated thyroid carcinoma with radiolabeled somatostatin analogs.
    Teunissen JJ; Kwekkeboom DJ; Krenning EP
    Trends Endocrinol Metab; 2006; 17(1):19-25. PubMed ID: 16311041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radionuclide therapy of cancer with radiolabeled antibodies.
    Boerman OC; Koppe MJ; Postema EJ; Corstens FH; Oyen WJ
    Anticancer Agents Med Chem; 2007 May; 7(3):335-43. PubMed ID: 17504159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic radionuclides in nuclear medicine: current and future prospects.
    Yeong CH; Cheng MH; Ng KH
    J Zhejiang Univ Sci B; 2014 Oct; 15(10):845-63. PubMed ID: 25294374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In- and Y-DOTA-lanreotide: results and implications of the MAURITIUS trial.
    Virgolini I; Britton K; Buscombe J; Moncayo R; Paganelli G; Riva P
    Semin Nucl Med; 2002 Apr; 32(2):148-55. PubMed ID: 11965610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peptide receptor imaging and therapy.
    Kwekkeboom D; Krenning EP; de Jong M
    J Nucl Med; 2000 Oct; 41(10):1704-13. PubMed ID: 11038002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ten years of experience with MIBG applications and the potential of new radiolabeled peptides: a personal overview and concluding remarks.
    Shapiro B
    Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):150-5. PubMed ID: 9002776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Nuclear medicine in oncotherapy].
    Pávics L; Besenyi Z
    Magy Onkol; 2015 Sep; 59(3):193-7. PubMed ID: 26339908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imaging of neuroendocrine tumors.
    Rufini V; Calcagni ML; Baum RP
    Semin Nucl Med; 2006 Jul; 36(3):228-47. PubMed ID: 16762613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Nuclear oncology with monoclonal antibodies and peptides].
    Hosono M
    Kaku Igaku; 1998 Oct; 35(8):681-7. PubMed ID: 9847509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radionuclide therapy beyond radioiodine.
    Gabriel M
    Wien Med Wochenschr; 2012 Oct; 162(19-20):430-9. PubMed ID: 22815123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peptide receptor radionuclide therapy for non-radioiodine-avid differentiated thyroid carcinoma.
    Teunissen JJ; Kwekkeboom DJ; Kooij PP; Bakker WH; Krenning EP
    J Nucl Med; 2005 Jan; 46 Suppl 1():107S-14S. PubMed ID: 15653659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Recent progress in radionuclide therapy].
    Kasagi K; Iwata M; Misaki T; Konishi J; Sakahara H
    Nihon Igaku Hoshasen Gakkai Zasshi; 2000 Nov; 60(13):729-37. PubMed ID: 11140321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The palliative role of 131I-MIBG and 111In-octreotide therapy in patients with metastatic progressive neuroendocrine neoplasms.
    Pasieka JL; McEwan AJ; Rorstad O
    Surgery; 2004 Dec; 136(6):1218-26. PubMed ID: 15657579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.